Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 4, 2005, Pages 214-217

  Ji, Sang Hoon ^a   Park, Young Suk ^a   Lee, Jeeyun ^a   Lim, Do Hyoung ^a   Park, Byeong Bae ^a   Park, Keun Woo ^a   Kang, Jung Hun ^a   Lee, Se Hoon ^a   Park, Joon Oh ^a   Kim, Kihyun ^a   Kim, Won Seog ^a   Jung, Chul Won ^a   Im, Young Hyuck ^a   Kang, Won Ki ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Irinotecan; Leucovorin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; RECURRENT CANCER; THROMBOCYTOPENIA; VOMITING; ADOLESCENT; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOPENIA; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20344389264     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyi061     Document Type: Article

References (25)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW, et al. Cancer incidence in Korea. Cancer Res Treat 2002;34:405-8.
3. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994;73:556-62.
4. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997;80:1179-87.
5. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997;15:389-400.
6. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
7. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
8. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14:1128-35.
9. Von Hoff DD, Rotheberg ML, Pitot HC, Elfring GL, Mohrland JS, Schaaf LJ, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997;16:228a (abstract 803).
10. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, et al. Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1995;14:709-18.
11. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
12. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg, Rubin RMJ, et al. A phase II trial of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15:2910-9.
13. Mullany S, Svingen PA, Kaufmann SH, Erlichmanet C. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998;42:391-9.
14. Guichard S, Hennebelle I, Bugat R, Canal P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998;55:667-76.
15. Mans DR, Grivicich I, Peters GJ, Schwartsmann G. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 1999;35:1851-61.
16. Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-8.
17. Vanhoefer U, Harstrick A, Kohne CH, Achterrath W, Rustum YM, Seeber S, et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999;17:907-13.
18. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
19. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
20. Benson AB III, Goldberg RM. Optimal use of the combination of irinotecan and 5-fluorouracil. Semin Oncol 2003;30:68-77.
21. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-7.
22. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001;345:144-5.
23. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
24. Koehne CH, Van Cutsem E, Wils JA, Bokemeyer C, El-Serafi M, Lutz M, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EOTC GI Group study 40986. Proc Am Soc Clin Oncol 2003;22:254A.
25. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.